CYP19A1 and breast carcinoma: Zaccheo et al (1991, 1993) have validated this principle by showing that Tam plus examestane, an aromatase inhibitor, was more effective than Tam alone in stopping breast cancer growth, and now combinations of Tam plus aromatase inhibitors are showing promise clinically (Abrial et al, 2006).